Zhejiang Ausun Pharmaceutical Co., Ltd.

603229

CNE100002XK2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-14 pm EDT			5-day change	1st Jan Change
9.9 ^CNY	-2.37%		-0.80%	-25.06%

2023	Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Year 2017

April 09, 2018

Zhejiang Ausun Pharmaceutical Co., Ltd. reported earnings results for the year 2017. For the year, the company reported basic earnings per share of CNY 0.37 and weighted average return on net assets of 12.43%.

Latest news about Zhejiang Ausun Pharmaceutical Co., Ltd.

Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.	23-05-08	CI
Ausun Pharma's Unit Passes Regulatory Inspection	23-05-08	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.	23-04-25	CI
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4%	23-01-19	MT
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine	23-01-17	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors	23-01-16	CI
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression	23-01-06	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index	22-09-19	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study	22-07-11	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding	22-03-07	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd.	22-03-07	CI
Algernon Pharmaceuticals Inc. Announces Award Contract to Zhejiang Ausun Pharmaceutical Co, Ltd of China to Begin the Manufacturing of Cgmp Supply of Its Repurposed Drug Candidate Np-251	22-02-23	CI
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction	22-02-11	MT
Ausun Pharma's Shareholder and Party Acting in Concert Plan to Unload 4.91% Stakes	21-11-24	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Marvel Biosciences : up 8.7% as Provides Update on Lead Candidate MB-204 Manufacturing	21-10-15	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-17	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021	21-04-27	CI

Chart Zhejiang Ausun Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Ausun Pharmaceutical Co., Ltd.

More charts

Company Profile

Zhejiang Ausun Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The Company is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.

Sector

Pharmaceuticals

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Ausun Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.9

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.	-25.06%	811M
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+23.91%	559B
JOHNSON & JOHNSON	-5.84%	356B
MERCK & CO., INC.	+15.75%	320B
ABBVIE INC.	+4.32%	286B
ASTRAZENECA PLC	+3.06%	213B
NOVARTIS AG	+0.12%	207B
ROCHE HOLDING AG	-9.04%	199B
PFIZER, INC.	-10.00%	147B

Other Pharmaceuticals